ReviewCurrent hematologic malignancy reports2021
Balancing Quality, Cost, and Access During Delivery of Newer Cellular and Immunotherapy Treatments.
Praveen Ramakrishnan Geethakumari et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
28 papers cite it
this paperpooled itcites it